Page last updated: 2024-12-08

schisantherin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID151529
CHEMBL ID404875
CHEBI ID9048
MeSH IDM0106473

Synonyms (34)

Synonym
gomisin
schisantherin a
gomisin c
58546-56-8
AC-11195
chebi:9048 ,
CHEMBL404875 ,
AC1L46IR ,
arisanschinin k
873480ks4a ,
(5s-(5alpha,6beta,7beta))-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-5,6-diol 5-benzoate
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, (5s-(5alpha,6beta,7beta))-
unii-873480ks4a
bdbm50418091
AKOS015897145
schizantherin a
schisantherin a (gomisin c) (constituent of northern schisandra) [dsc]
benzo(3,4)cycloocta(1,2-f)(1,3)benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, (5s,6s,7s,13as)-
CS-3660
HY-N0694
molport-005-932-873
DTXSID70207261
schizantherin-a
wuweizi ester-a
gomisin-c
wuweizi ester a
(5s,6s,7s)-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-5-yl benzoate
Q27108251
mfcd09026937
BCP15178
G0538
[(8s,9s,10s)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] benzoate
AC-34833
schisantherin a (gomisin c) (constituent of northern schisandra)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tanninAny of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Ki0.39900.00011.41629.9000AID589121
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID313800Antiproliferative activity against human A549 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID1698209Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in heart weight ratio at 10 mg/kg, po administered via gavage for 30 days2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID313799Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID313794Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID335886Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID335885Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID1698220Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in collagen in heart at 10 mg/kg, po administered via gavage for 30 days by Masson trichrome staining based microscopic met2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698213Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in ejection fraction at 10 mg/kg, po administered via gavage for 30 days by echocardiography2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698207Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in myocardial necrotic area at 10 mg/kg, po administered via gavage for 30 days2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698211Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in left ventricular function by measuring reduction in LAD-induced anterior wall weakened at 10 mg/kg, po administered via 2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698225Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in CTGF mRNA expression at 10 mg/kg, po administered via gavage for 30 days by RT2 Profiler PCR Array2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698226Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in Lox mRNA expression at 10 mg/kg, po administered via gavage for 30 days by RT2 Profiler PCR Array2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID335889Cytotoxicity against human Raji cells at 1000 mol ratio by trypan blue staining method2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID1698206Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in organized myocardial cells at 10 mg/kg, po administered via gavage for 30 days by H and E staining based optical microsc2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698217Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as reduction in infarct survival area of myocardial cells at 10 mg/kg, po administered via gavage for 30 days by H and E staining based2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID589121Mechanism based inhibition of human cytochrome P450 3A4 measured by N-demethylation of erythromycin2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1698214Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in fractional shortening at 10 mg/kg, po administered via gavage for 30 days by echocardiography2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID313798Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID313795Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID335888Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID724309Cytotoxicity against rat HSC-T6 cells2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Anti-liver fibrotic lignans from the fruits of Schisandra arisanensis and Schisandra sphenanthera.
AID1698224Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in Col3a1 mRNA expression at 10 mg/kg, po administered via gavage for 30 days by RT2 Profiler PCR Array2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID313797Antiproliferative activity against human T47D cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
AID335887Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 mol ratio relative to TPA2002Journal of natural products, Sep, Volume: 65, Issue:9
Interiotherins C and D, two new lignans from Kadsura interior and antitumor-promoting effects of related neolignans on Epstein-Barr virus activation.
AID1698222Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in collagen volume fraction at 10 mg/kg, po administered via gavage for 30 days by Masson trichrome staining based microsco2020Journal of natural products, 10-23, Volume: 83, Issue:10
Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID724310Inhibition of NF-kappaB (unknown origin) expressed in TNFalpha-stimulated rat HSC-T6 cells assessed as reduction of HSC activation at 50 ug/ml treated 30 mins before TNFalpha stimulation measured after 6 hrs by bioluminescence based luciferase reporter ge2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Anti-liver fibrotic lignans from the fruits of Schisandra arisanensis and Schisandra sphenanthera.
AID313796Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.93 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]